Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & Administrative
Others
Ratios

Odyssey Health (ODYY) EBITDA (2016 - 2021)

Odyssey Health has reported EBITDA over the past 8 years, most recently at -$2.6 million for Q3 2021.

  • Quarterly results put EBITDA at -$2.6 million for Q3 2021, down 125.45% from a year ago — trailing twelve months through Jul 2021 was -$15.9 million (down 312.32% YoY), and the annual figure for FY2025 was -$1.0 million, up 52.29%.
  • EBITDA for Q3 2021 was -$2.6 million at Odyssey Health, up from -$12.1 million in the prior quarter.
  • Over the last five years, EBITDA for ODYY hit a ceiling of -$26029.0 in Q1 2017 and a floor of -$23.4 million in Q3 2019.
  • Median EBITDA over the past 5 years was -$231760.0 (2018), compared with a mean of -$2.3 million.
  • Biggest five-year swings in EBITDA: plummeted 28500.69% in 2019 and later skyrocketed 95.06% in 2020.
  • Odyssey Health's EBITDA stood at -$49497.0 in 2017, then dropped by 5.87% to -$52404.0 in 2018, then tumbled by 2424.08% to -$1.3 million in 2019, then skyrocketed by 60.29% to -$525269.0 in 2020, then tumbled by 396.38% to -$2.6 million in 2021.
  • The last three reported values for EBITDA were -$2.6 million (Q3 2021), -$12.1 million (Q2 2021), and -$633792.0 (Q1 2021) per Business Quant data.